2002
DOI: 10.1517/14712598.2.3.237
|View full text |Cite
|
Sign up to set email alerts
|

Current status of adoptive immunotherapy of malignancies

Abstract: Adoptive immunotherapy involves the transfer of immune effectors with antitumour activity into the tumour bearing host. Early approaches such as lymphokine activator killer (LAK) cells and tumour infiltrating lymphocytes (TILs) have yielded occasional clinical responses. More recently, attempts to stimulate and/or select antigen-specific T-cells in vitro have demonstrated that tumour-specific adoptive immunotherapy is possible. These approaches require complicated and time consuming in vitro stimulation proced… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
8
0

Year Published

2004
2004
2015
2015

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 19 publications
(8 citation statements)
references
References 52 publications
0
8
0
Order By: Relevance
“…16,17 With rapid advances in technology in molecular biology, adoptive cancer immunotherapy using CIK cells is receiving attention. 13,18 This technique may have a renew interests in light of the expression of programmed cell death 1 (PD1) pathway in HCC and recent encouraging outcome demonstrated in patients treated with Nivolumab. 19,20 An international registry of clinical trials on CIK was established in 2010 by SchmidtWolf et al, with an aim to collect clinical data and standardize treatment of patients with cancer using CIK cells.…”
Section: Discussionmentioning
confidence: 99%
“…16,17 With rapid advances in technology in molecular biology, adoptive cancer immunotherapy using CIK cells is receiving attention. 13,18 This technique may have a renew interests in light of the expression of programmed cell death 1 (PD1) pathway in HCC and recent encouraging outcome demonstrated in patients treated with Nivolumab. 19,20 An international registry of clinical trials on CIK was established in 2010 by SchmidtWolf et al, with an aim to collect clinical data and standardize treatment of patients with cancer using CIK cells.…”
Section: Discussionmentioning
confidence: 99%
“…These cells have been widely used in previous clinical studies; however, there have been no systematic comparative evaluations of the two treatments (7,8). Therefore, the present study aimed to compare the antitumor effects of CAPRI and CIK cells in vitro , through investigating cell morphology, proliferation, cytotoxic activity to tumor cells and the ability of these cells to secrete cytokines.…”
Section: Introductionmentioning
confidence: 99%
“…macrophages). Lymphokine-activated killer (LAK) cells, a type of white blood cells that are stimulated in a laboratory to kill tumor cells, have been explored for cancer immunotherapy [50]. Tracking of GFP-labeled LAK cells in mice carrying B16 melanoma metastases has been reported [51].…”
Section: Tracking Of Immune Cellsmentioning
confidence: 99%